Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy

Musa Khaitov, Igor Shilovskiy, Rudolf Valenta, Milena Weber, Artem Korneev, Inna Tulaeva, Pia Gattinger, Marianne van Hage, Gerhard Hofer, Jon R Konradsen, Walter Keller, Oluwatoyin Akinfenwa, Alina Poroshina, Nataliya Ilina, Elena Fedenko, Olga Elisyutina, Alla Litovkina, Evgenii Smolnikov, Aleksandra Nikonova, Sergei RybalkinVladimir Aldobaev, Valeriy Smirnov, Nadezhda Shershakova, Olga Petukhova, Dmitriy Kudlay, Artem Shatilov, Anastasiya Timofeeva, Raffaela Campana, Sergei Udin, Veronica Skvortsova

Research output: Journal article (peer-reviewed)Journal article

2 Citations (Scopus)


BACKGROUND: IgE cross-sensitization to major birch pollen allergen Bet v 1 and pathogenesis-related (PR10) plant food allergens is responsible for the pollen-food allergy syndrome.

METHODS: We designed a recombinant protein, AB-PreS, consisting of non-allergenic peptides derived from the IgE-binding sites of Bet v 1 and the cross-reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB-PreS was expressed in E. coli and purified by chromatography. The allergenic and inflammatory activity of AB-PreS was tested using basophils and PBMCs from birch pollen allergic patients. The ability of antibodies induced by immunization of rabbits with AB-PreS and birch pollen extract-based vaccines to inhibit allergic patients IgE binding to Bet v 1 and Mal d 1 was assessed by ELISA.

RESULTS: IgE-binding experiments and basophil activation test revealed the hypoallergenic nature of AB-PreS. AB-PreS induced lower T-cell activation and inflammatory cytokine production in cultured PBMCs from allergic patients. IgG antibodies induced by five injections with AB-PreS inhibited allergic patients' IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract-based vaccines. Additionally, immunization with AB-PreS induced HBV-specific antibodies potentially protecting from infection with HBV.

CONCLUSION: The recombinant AB-PreS-based vaccine is hypoallergenic and superior over currently registered allergen extract-based vaccines regarding the induction of blocking antibodies to Bet v 1 and Mal d 1 in animals.

Original languageEnglish
Pages (from-to)1001-1017
Number of pages17
JournalAllergy: European Journal of Allergy and Clinical Immunology
Issue number4
Early online date19 Oct 2023
Publication statusE-pub ahead of print - 19 Oct 2023


Dive into the research topics of 'Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy'. Together they form a unique fingerprint.

Cite this